

SARC SEMIANNUAL MEETING

FRIDAY, MAY 29, 2026 ♦ 7:30 AM-12 NOON CENTRAL

Northwestern Memorial Hospital, Feinberg Conference Center 3rd Floor 251 E. Huron Street, Chicago, IL, USA

7:30-8:55 am	Breakfast & Networking	Feinberg Krumlovsky Atrium
9:00-9:10 am	Welcome	Feinberg ABCD Conference Room
	<i>Opening Remarks</i>	Steven Young (SARC CEO) Jonathan Fletcher MD (SARC CSO; BWH, Harvard)
9:10-10:20 am	Session 1: Precision Delivery in Sarcoma: Targets, Modalities, Clinical Contexts	
Introduction	<i>Moderator</i>	Breelyn Wilky MD (U Colorado)
<ul style="list-style-type: none"> ○ Target identification & validation: Surfaceome & ADC ○ Integrating radiopharmaceuticals in the combined modality treatment of patients with sarcoma ○ Bispecific Antibodies for Alpha Therapy 		Richard Gorlick MD (MDACC) Zachary Morris MD PhD (U. Wisconsin)
	<i>Discussion: Panel & Audience</i>	TBD
10:20-11:40 am	Session 2: SARC Studies & Programs	Presenters
	<i>Session Chair</i>	Scott Okuno MD (SARC CMO; Mayo Clinic)
SARC Operations:		
<ul style="list-style-type: none"> ○ Clinical Trials Development Committee <ul style="list-style-type: none"> ▪ Internal and external developing trials ▪ Mentoring junior staff for clinical trials 		Gregory Cote MD PhD (MGH) & Elizabeth Davis MD (Vanderbilt)
SARC Programs & Initiatives:		
<ul style="list-style-type: none"> ○ Strategic Collaborations Outside the USA ○ SARC_{TALK} The Patient Experience 		Scott Okuno MD & TBD Daphne Edgren (Northwestern U., Harvard)
SARC Clinical Trials Updates:		Scott Okuno MD &/or Principal Investigators
<ul style="list-style-type: none"> ○ Open/Actively Accruing <ul style="list-style-type: none"> ▪ SARC045 Ph II Tebentafusp Advanced CCS ▪ SARC046 Ph II Nab-Sirolimus in EHE ○ Open/Completed Accrual <ul style="list-style-type: none"> ▪ SARC044 Ph II Bezuclastinib w/Sunitinib in GIST ▪ SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS ○ Closed/Pending Publication <ul style="list-style-type: none"> ▪ SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES ▪ SARC038 Ph II Regorafenib & Nivolumab in OS ○ Pending Launch <ul style="list-style-type: none"> ▪ SARC048 Ph III Neoadjuvant Doxorubicin & Ifosfamide STS ▪ SARC049 Ph II Zanzalintinib Advanced MPNST 		Sandra D'Angelo MD (MSKCC) & Andrea Napolitano MD PhD (Royal Marsden) Michael Wagner MD (DFCI) Candace Haddox MD (DFCI) Mark Dickson MD (MSKCC) Patrick Grohar MD PhD (U. of MI) Fariba Navid MD (CHLA) Lara Davis MD (Fred Hutch) David Liebner MD (OSU) Vanessa Eulo MD (UAB) & Angela Hirbe MD PhD (WashU)
11:40-11:55 am	Session 3: Keynote	
	<i>Author, Speaker, Cancer Survivor, Veteran</i>	Brandi Benson
11:55 am-12:00 pm	Closing Remarks/Adjourn	SARC Leadership